Cargando…
Nabilone for non-motor symptoms of Parkinson’s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study)
Although open-label observations report a positive effect of cannabinoids on non-motor symptoms (NMS) in Parkinson’s disease (PD) patients, these effects remain to be investigated in a controlled trial for a broader use in NMS in PD patients. Therefore, we decided to design a proof-of-concept study...
Autores principales: | Peball, Marina, Werkmann, Mario, Ellmerer, Philipp, Stolz, Raphaela, Valent, Dora, Knaus, Hans-Günther, Ulmer, Hanno, Djamshidian, Atbin, Poewe, Werner, Seppi, Klaus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647387/ https://www.ncbi.nlm.nih.gov/pubmed/31129719 http://dx.doi.org/10.1007/s00702-019-02021-z |
Ejemplares similares
-
Effects of Nabilone on Sleep Outcomes in Patients with Parkinson's Disease: A Post‐hoc Analysis of NMS‐Nab Study
por: Peball, Marina, et al.
Publicado: (2022) -
Non‐Motor Symptoms in Parkinson's Disease are Reduced by Nabilone
por: Peball, Marina, et al.
Publicado: (2020) -
Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study
por: Ellmerer, Philipp, et al.
Publicado: (2022) -
Different assessment tools to detect sarcopenia in patients with Parkinson's disease
por: Valent, Dora, et al.
Publicado: (2022) -
Nomogram to Predict the Probability of Functional Dependence in Early Parkinson’s Disease
por: Valent, Dora, et al.
Publicado: (2023)